News
Fidaxomicin favored over vancomycin in real-world C. diff study
Researchers compared the agents for treating both initial and recurrent Clostridioides difficile infections in a Medicare population.
News
Fidaxomicin favored over vancomycin in real-world C. diff study
Researchers compared the agents for treating both initial and recurrent Clostridioides difficile infections in a Medicare population.
News
More evidence dementia not linked to PPI use in older people
Investigators assessed almost 19,000 older adults for use of PPI or H2RA medications and risk for incident dementia or cognitive decline over time...
News
IBD after age 60: More evidence antibiotics play a role
IBD “should be considered, especially if you have a patient who’s reporting multiple courses of antibiotics in the last few years.”
News
Science says this is the ‘most boring person in the world’
People who work in banking, finance, accounting, data analytics, and cleaning topped the most boring list in the study.
News
Upadacitinib reduces extraintestinal manifestations of ulcerative colitis: Study
Researchers evaluated phase 3 data comparing the oral JAK inhibitor with placebo for treating extraintestinal manifestations.
News
Too much marijuana can make you unpleasantly, dangerously sick
The bouts of vomiting, in particular, can get so severe that people can end up hospitalized with dehydration, electrolyte disorders, and weight...
News
Promising leads to crack long COVID discovered
It’s likely that research will show long COVID is a condition with more than one cause, experts said.
News
Q&A: Long COVID symptoms, management, and where we’re headed
Long COVID continues to be a moving target – continuously evolving and still...
News
FDA grants full approval to Moderna COVID-19 vaccine
The Moderna vaccine also now has a new trade name: Spikevax.
News
Billionaire Mark Cuban launches online pharmacy for generics
The new venture plans to charge consumers 15% above the manufacturing cost for the generic medications.
News
Long COVID is real, and many real questions remain
It remains unclear if a hyperinflammatory response is driving persistent post-COVID-19 symptoms.
News
Watch, but don’t worry yet, about new Omicron subvariant
Expert predictions about BA.2 vary widely, from worry to cautious optimism.